Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
From Fixed to SyncAV: Evaluating the Real-World Effects on CRT Patients
Session:
Sessão de Posters 53 - Otimização de CRT em 2026
Speaker:
Sofia Esteves
Congress:
CPC 2026
Topic:
C. Arrhythmias and Device Therapy
Theme:
09. Device Therapy
Subtheme:
09.3 Cardiac Resynchronization Therapy
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Sofia Esteves; Marta Vilela; Joana Brito; Susana Gonçalves; Ana Bernardes; Sara Coutro Pereira; Pedro Silvério António; Nelson Cunha; João de Sousa; Andreia Magalhães; Fausto J. Pinto; Pedro Marques
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-family:"Calibri",sans-serif">Introduction: </span></strong><span style="font-family:"Calibri",sans-serif">Optimizing atrioventricular (AV) timing is a key factor in maximizing cardiac resynchronization therapy (CRT) benefits. While initial AV programming may be fixed, individualized AV-synchronous pacing with the SyncAV algorithm could provide additional hemodynamic advantages. The long-term effects of switching from fixed AV delay to SyncAV remain unclear. </span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-family:"Calibri",sans-serif">Aim</span></strong><span style="font-family:"Calibri",sans-serif">: To compare clinical outcomes, echocardiographic and electrocardiographic changes of CRT patients initially programmed with fixed AV delay and subsequently switched to SyncAV. </span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-family:"Calibri",sans-serif">Methods:</span></strong><span style="font-family:"Calibri",sans-serif"> This was a prospective follow-up trials that include patients with a CRT programmed with fixed AV delay for 12 months who underwent switch to SyncAV algorithm. Primary endpoints included the composite of all-cause mortality and hospitalizations. Secondary endpoints included changes in QRS and echocardiographic parameters.</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-family:"Calibri",sans-serif">Results: </span></strong><span style="font-family:"Calibri",sans-serif">We included 62 patients (52.9% male), with a mean age of 68.9± 9.6 years. 72.9% of the patients had dilated cardiomyopathy and 78.6% were on functional class II of the NYHA. At baseline, the mean left ventricular ejection fraction (LVEF) was 48.5%, the mean intrinsic QRS was 157 ms and the median percentage of biventricular pacing (BIV) was 99%. The baseline heart failure medications and comorbidities are in <strong><u>Table 1</u></strong>. After 12 months follow up, the primary endpoint occurred in 13 patients. When comparing our patients with those who had CRT with SyncAV activated from device implantation, no differences in clinical events were observed, suggesting that the SyncAV algorithm is not associated with clinical benefit in CRT patients, regardless of the duration of algorithm activation- <strong><u>Graph 1</u></strong>. Considering the secondary endpoints, after 12 months of SyncAV activation, median intrinsic QRS duration was reduced by 7 ms relative to baseline values and median QRS duration in pacing was reduced by 14 ms. The SyncAV algorithm was associated with modest improvement in LVEF (+ 4.1%) and index left ventricular end systolic volume (1.1 mL/m<sup>2</sup>)- <strong><u>Table 2.</u></strong></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-family:"Calibri",sans-serif">Conclusion:</span></strong><span style="font-family:"Calibri",sans-serif"> Switching to the SyncAV algorithm in CRT patients previously on fixed AV delay led to additional QRS shortening. However, this did not translate into significant left ventricular reverse remodelling nor clinical benefit at 1 year.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site